^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

Published date:
12/03/2022
Excerpt:
...high baseline serum IL-6 levels were associated with worse survival outcomes and reduced T-cell responses in Pembro/Axi-treated advanced RCC patients.
DOI:
10.3390/cancers14235985